Comparison of Methods to Facilitate Rapid Sequence Intubation

NCT ID: NCT01479751

Last Updated: 2012-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, methods which are known for facilitating rapid sequence intubation or accelerating rocuronium (Roc)onset are compared including magnesium (Mg), ketamine pretreatment, large dose rocuronium and priming.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients are pretreated with Mg, ketamine, or priming dose Roc. Two groups do not receive pretreatment, but are given Roc 0.6 mg/kg or 0.9 mg/kg.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intubating Condition

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Rocuronium magnesium priming ketamine intubation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ketamine

Patients receive ketamine 0.5 mg/kg 2 min before Roc injection.

Group Type EXPERIMENTAL

Ketamine

Intervention Type DRUG

patients receive ketamine 0.5 mg/kg 2 min before Roc injection.

priming

Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.

Group Type EXPERIMENTAL

rocuronium

Intervention Type DRUG

Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.

Roc 0.9

Patients receive Roc 0.9 mg/kg as an induction dose.

Group Type NO_INTERVENTION

No interventions assigned to this group

Control

Patients receive Roc 0.6 mg/kg without any pretreatments of Mg, ketamine, or priming.

Group Type NO_INTERVENTION

No interventions assigned to this group

Mg

Patients receive magnesium sulfate (MgSO4) 50 mg/kg over 10 min before Roc injection.

Group Type EXPERIMENTAL

Magnesium Sulfate

Intervention Type DRUG

Patients receive MgSO4 50 mg/kg for 10 min before injection of Roc 0.6 mg/kg.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnesium Sulfate

Patients receive MgSO4 50 mg/kg for 10 min before injection of Roc 0.6 mg/kg.

Intervention Type DRUG

Ketamine

patients receive ketamine 0.5 mg/kg 2 min before Roc injection.

Intervention Type DRUG

rocuronium

Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 18 - 65 years,
* ASA 1 - 2,
* patients scheduled for elective surgery under general anesthesia,
* BMI 18.5-24.9 kg/m2
* Mallampati class I-II

Exclusion Criteria

* neuromuscular disorder,
* cardiac/hepatic/renal insufficiency,
* pregnant.
* anticipated difficult airway
* medications that influence neuromuscular transmission
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Seoul National University Bundang Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kim Mihyun

clinical professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mihyun Kim, doctor

Role: PRINCIPAL_INVESTIGATOR

Seoul National University Bundang Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Seoul National University Bundang hopital

Seongnam-si, Gyeonggi-do, South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

facilitating RSI

Identifier Type: -

Identifier Source: org_study_id